As we have reached the end of the first full week of April, we review moves from smid-cap biopharma companies during this past week as well as March as a whole. See Table 1 for weekly moves and moves YTD for companies and categories on BPIQ.com compared to XBI.
Table 1. BPIQ company weekly/monthly moves and YTD moves
Highlights for the week of 4/4-4/8
Biggest positive move
$PLX +42.9% Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Topline Results from the 24-Month Phase III BALANCE Clinical Trial of PRX-102 for the Treatment of Fabry Disease.
Biggest negative move
$KLDO -84.1% Kaleido Biosciences, Inc. (the “Company”) delivered formal notice to The Nasdaq Stock Market, Inc. that the Company intends to voluntarily delist its common stock.
Additional big moves
$BCYC +24.5% Bicycle Therapeutics to Present Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting.
$LYRA +22.2% LYRA THERAPEUTICS ANNOUNCES $100.5 MILLION PRIVATE PLACEMENT.
$WVE +14.3% Wave Life Sciences Announces Positive Update to Ongoing Phase 1b/2a FOCUS-C9 Study Driven by Potent, Durable Reductions of Poly(GP) with Low, Single Doses of WVE-004.
$PGEN +11.5% Precigen Receives Fast Track Designation for PRGN-3006 UltraCAR-T® in Patients with Relapsed or Refractory Acute Myeloid Leukemia.
$BBIO +10.8% BridgeBio Pharma Presents Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM).
$IMCR +10.6% European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma.
$KDNY -11.0% Chinook Therapeutics, IgA Nephropathy Foundation and Komodo Health Collaborate to Provide Nephrologists with Support and Information to Help Reduce Barriers to Diagnosis and Care.
$RYTM -16.3% Rhythm Pharmaceuticals Optimizes Design of EMANATE and DAYBREAK Clinical Trials to Advance Setmelanotide for Rare Genetic Diseases of Obesity.
$IMRA -22.1% Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia.
$ZNTL -30.0% Zentalis Pharmaceuticals Announces Positive Initial Clinical Data on ZN-c3, its Wee1 Inhibitor, in Patients with Advanced Ovarian Cancer at AACR.
$CRIS -33.3% Curis Announces FDA Partial Clinical Hold for TakeAim Leukemia Study of Emavusertib (CA-4948).
$BCRX -37.8% BioCryst Pauses Enrollment in BCX9930 Clinical Trials.
$RUBY -45.6% Rubius Therapeutics Reports Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors Demonstrating Single-Agent Activity and Favorable Tolerability.
$APTX -49.2% Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy
$CCCC -50.6% C4 Therapeutics Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical Trial of CFT7455, a Novel IKZF1/3 Degrader.
$GNCA -69.2% Genocea Presents Encouraging Initial Data from GEN-011 Phase 1/2a Trial at AACR 2022.
$BTAI BioXcel Therapeutics Announces FDA Approval of IGALMI™ (dexmedetomidine) Sublingual Film for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in Adults.
$BTAI was an April BPIQ Big Mover; See the asset's IQ card for more info HERE
Highlights for next week
$ALNY Vutrisiran PDUFA
$SCPH Furoscix NDA resubmission
$NKTR Bempeg Phase 3 data
AACR began today (4/8) and runs through 4/13. Subscribe to see our full forum post highlighting companies presenting this weekend HERE
To see next week's Big Movers HERE, subscribe. Learn more here.
See our Big Movers post to learn about upcoming Movers throughout April and PDUFAs, after subscribing. Learn more here.
Comentarios